45 results about "Promoter methylation" patented technology

Described here are methods to utilize genomic and epigenomic detection platforms to provide quantitative metrics, including those representative of molecular phenotypes, in a variety of iimmuno-oncology applications, including those related to the characterization of patient responsiveness, treatment efficacy, adverse events among otheres. In various embodiments, described herein is an example of generating prognostic and t outcomes of a cfDNA-derived promoter methylation score in predicting ICI benefit.

The invention discloses TCN1 (Trancobalamin 1, cobalamin 1) and application of an inhibitor of the TCN1 in preparation of products for diagnosing and treating diseases of an autoimmune system. According to the invention, expression in psoriasis tissues is up-regulated and promoter DNA methylation is down-regulated into genes to screen TCN1 genes, an over-expression TCN1 HaCaT cell line is constructed, and it is verified that the over-expression TCN1 HaCaT cell line participates in keratinocyte proliferation and IL-17 activation as an autoantigen, can be used as a diagnostic marker and a therapeutic target of autoimmune skin diseases such as psoriasis and the like, and has broad application prospects. And a new direction is provided for mechanism research and treatment of autoimmune skin diseases such as psoriasis.

The invention belongs to the technical field of biological detection, and particularly relates to a biomarker composition and application thereof in methylation detection of an MGMT promoter. The biomarker composition is prepared from phospholipid (L5PL), creatinine (Creatinine) and ornithine (Ornithine) in the LDL-5 sub-component, and the biomarker composition is prepared from the phospholipid (L5PL), the creatinine (Creatinine) and the ornithine (Ornithine). Whether a glioblastoma patient carries MGMT promoter methylation or not is judged through a plurality of biomarkers, the method has the advantages of being good in sensitivity and specificity, small in patient trauma, capable of overcoming individual differences and the like, and a new solution is provided for prognosis evaluation of glioblastoma.

The invention belongs to the technical field of biology, and particularly relates to a construction method of epigenome edited zebrafish, sgRNA of a targeted zebrafish runx2b gene promoter region and application of the sgRNA. The invention provides a construction method of epigenome edited zebrafish, which comprises the step of carrying out methylation editing by using a CRISPR / dCas9-methyltransferase system targeting runx2b gene promoter region, thereby inhibiting runx2b gene expression and reducing intermuscular bone formation. According to the method, the expression level of the runx2b gene is accurately regulated and controlled through an epigenetic editing technology on the premise that a DNA sequence is not changed, and formation of fish intermuscular bones is effectively reduced. The zebra fish F0 treated by the method represents that the runx2b mRNA expression level is obviously reduced, and the intermuscular bones of the eleventh to sixteenth sarcomedo regions of adult F0 generation fish are obviously shorter than those of a control group, and the shortening range reaches 23.3% to 38.8%. Besides, the method provides theoretical basis and technical support for improving fish economic traits by accurately regulating and controlling the expression mode of the key economic trait gene and simultaneously keeping the integrity of genome DNA (Deoxyribose Nucleic Acid).

The present invention relates to a DNA methylation editing system and application thereof based on CRISPR / dCas9 and applicable to half-smooth tongue sole, belonging to the field of gene editing technology, wherein the system comprises a Fuw-UbC-dCas9-dnmt3a plasmid and a pGL3-U6-sgRNAs plasmid, wherein the dnmt3a gene sequence is shown in SEQ ID NO.1. The present invention also provides an editing system and application of the system in the half-smooth tongue sole emx2 gene, as well as guide RNAs sgRNA1 and sgRNA3. Both single transfection sgRNA and mixed transfection sgRNAs can effectively increase the promoter DNA methylation level of the emx2 gene, which increases by about 30%, 15.63% and 17.51%, respectively.

The invention provides application of GW5 gene promoter methylation based on a multi-omics gene mining technology in regulation and control of rice grain length, and relates to the technical field of biology. On the basis of a generic genome micro-core germplasm population, multi-dimensional omics data such as a genome and an epigenome are integrated, a rice epigenome map is constructed, a stable methylation polymorphism marker in the map is utilized, a rice grain width phenotype is combined to carry out multi-omics association analysis, a new epigenetic allele of the GW5 gene is successfully mined, and the GW5 gene is successfully identified. It is found that the upstream promoter region of the GW5 gene has two epigenetic states of hypermethylation and hypomethylation in different rice germplasm backgrounds, and after demethylation editing is carried out on the region, the phenotype that the grain length is remarkably increased is shown. Therefore, detection of the rice grain length character can be realized according to the promoter methylation level of the GW5 gene, and regulation and control of the rice grain length character can be realized by regulating and controlling the promoter methylation level of the GW5 gene.

A method and apparatus for detecting MGMT promoter methylation in glioblastoma, relating to the field of Raman spectroscopic detection. The method comprises: performing Raman spectral scanning on a glioma tissue sample to be detected to obtain Raman spectral data; preprocessing the Raman spectral data to obtain normalized Raman spectral data; extracting intensity values at characteristic shifts from the normalized Raman spectral data; and inputting the intensity values at the characteristic shifts into a classification model to calculate a classification prediction value, the classification prediction value being used for assisting in determining the MGMT promoter methylation state of said glioma tissue sample. The effect of the present application is that low-cost, non-destructive and accurate detection of the MGMT promoter methylation state of glioblastoma can be achieved.

The present application discloses a method and device for detecting methylation of MGMT promoter of glioblastoma, which relates to the field of Raman spectrum detection. The method comprises: performing Raman spectrum scanning on a glioma tissue sample to be tested to obtain Raman spectrum data; preprocessing the Raman spectrum data to obtain normalized Raman spectrum data; extracting the intensity value at the characteristic displacement from the normalized Raman spectrum data; inputting the intensity value at the characteristic displacement into a classification model, calculating and obtaining a classification prediction value, which is used to assist in determining the methylation state of MGMT promoter of the glioma tissue sample to be tested. The present application can realize low-cost, non-destructive and accurate detection of methylation state of MGMT promoter of glioblastoma.

The invention discloses application of a PLAC8 promoter methylation promoter in preparation of a product for promoting angiogenesis of a pig placenta, and belongs to the technical field of biological medicines. Experiments prove that PLAC8 as an anti-angiogenesis factor can directly inhibit the angiogenesis function, and DNMT3A can promote placenta vascular development and improve sow farrowing performance by regulating the methylation level of a PLAC8 promoter. In addition, it is determined that daily ration supplementation of methyl donors in the pig placenta vascular development peak period is an important nutrition way for improving DNA methylation of the PLAC8 promoter region. According to the method, the placenta injury mechanism under the adverse pregnancy outcome is directly determined through combination of in-vivo and in-vitro experiments, a theoretical basis is provided for analysis of a regulation strategy for promoting pig placenta angiogenesis and improving sow reproductive performance from epigenetics, and the accuracy and credibility of a result are improved.

The invention belongs to the technical field of biological medicine, provides a mustard gas immunotoxicity evaluation method based on Foxp3 promoter methylation, and evaluates the application effect of the Foxp3 promoter methylation level in mustard gas immunotoxicity evaluation in combination with in-vitro cell experiments and in-vivo animal experiments. Results show that Treg cell deficiency is a main reason for tissue damage and inflammation caused by mustard gas poisoning, cell fate and functions of the Treg cell deficiency are mainly regulated and controlled by Foxp3 transcription factors, mustard gas can cause increase of the DNA methylation level of Foxp3 gene loci, DNA hypermethylation of Foxp3 promoters is crucial to Treg cell differentiation inhibition, Th17 / Treg imbalance and systemic inflammation caused by mustard gas exposure, and the Treg cell deficiency is a main reason for tissue damage and inflammation caused by mustard gas poisoning. The methylation level of the Foxp3 promoter can be used as a marker of a mustard gas immunotoxicity evaluation method.

This invention provides GW2 The application of gene promoter methylation in regulating rice grain width belongs to the field of genetic engineering technology. This invention is based on the discovery of rice... ddm1 Methylation mutation sites in mutants were successfully identified. GW2 A novel epigenetic allelic variant was discovered. GW2 The DNA methylation status of a segment of the upstream promoter region of a gene corresponds to the grain width phenotype in rice. This invention utilizes an epigenetic editing system to demethylate a hypermethylated region in wide-grained rice, resulting in a significantly reduced grain width phenotype. Therefore, by regulating... GW2 GW2 Gene promoter methylation levels can enable precise regulation of rice grain width traits.

The invention discloses an MGMT gene promoter methylation detection kit and application in temozolomide curative effect predication, the kit performs primer design for MGMT gene promoter methylation sites related to temozolomide curative effect predication, the detection result covers 12 CPG islands of an MGMT gene, and the accuracy is high. And the detection primer is a common PCR primer and is low in price. According to the present invention, the gold standard pyrosequencing is performed, the positive-negative determination standard for detecting the MGMT gene promoter methylation based on the nucleic acid mass spectrometry platform is constructed, and the kit can provide the MGMT degree so as to provide the reference for the temozolomide therapy drug.

The invention provides an RhAG promoter methylation regulatory protein and application thereof in development regulation of Chinese rose petals. Specifically, the invention provides an RhAG promoter methylation regulatory protein RhDRM2, RhBIM1 or RhBIM2, or a coding nucleotide sequence, an expression vector or a host cell thereof, and application of the RhAG promoter methylation regulatory protein RhDRM2, RhBIM1 or RhBIM2 in Chinese rose petal regulation or RhAG promoter methylation regulation, especially application of the RhAG promoter methylation regulatory protein RhDRM2, RhBIM1 or RhBIM2 in low temperature induction resistance or double petal flower breeding. The invention provides an effective genetic engineering breeding means for low-temperature-resistant variety or double-petal breeding of Chinese rose, and has a wide application prospect.

Disclosed are methods and systems for detecting methylation of the promoter of O-6-methylguanine-DNA methyltransferase gene (MGMT). In particular, the methods and systems may be utilized to detect methylation in the MGMT promoter in a DNA sample from a glioblastoma and optionally in order to predict whether a subject having the glioblastoma will respond to treatment with an alkylating agent. The methods and systems typically include a step of deep-sequencing the DNA sample after the DNA sample has been treated with a reagent that converts unmethylated cytosine to uracil such as a bisulfite reagent.

The application provides a multi-omics gene mining technology-based method for detecting and regulating rice grain length GW5 The application relates to the technical field of biology, and relates to application of gene promoter methylation in regulation of rice grain length. The application is based on a pan-genome micro-core germplasm population, integrates multi-dimensional omics data such as genomes and epigenomes, constructs an epigenome atlas of rice, and uses stable methylation polymorphic markers in the atlas to combine with a rice grain width phenotype to perform multi-omics correlation analysis, successfully mines a new epiallele of a gene, discovers GW5 a new epiallele of a gene, and discovers GW5 that a high-methylation and low-methylation epigenetic state exists in an upstream promoter region of the gene in different rice germplasm backgrounds, and that after demethylation editing is performed on the region, a phenotype of significantly increased grain length is exhibited. Therefore, according to GW5 a methylation level of a promoter of the gene, detection of a rice grain length trait can be realized, and by regulating GW5 a methylation level of a promoter of the gene, regulation of a rice grain length trait can be realized.

The present invention relates to a composition for diagnosing liver cancer using a methylation change of a SORT1 gene promoter and a use thereof, and the present invention has enabled: establishment of a systematic research method and technique for investigating growth and proliferation of liver cancer, apoptosis, metastasis inhibition, and a signaling pathway; confirmation of whether SORT1, which is a target gene, shows clinical significance, on the basis of a basic experiment; and prediction or diagnosis of liver cancer with high accuracy by measuring the methylation degree of the SORT1 gene, specifically cg16988986 in a promoter region of the SORT1 gene. Therefore, a methylation change of the SORT1 gene promoter is highly likely to be used as a target for diagnosing liver cancer.

The present invention relates to a primer pair for detecting the DNA methylation level of the promoter of the sheep KAP8 gene, and an application and a methylation detection method thereof, and belongs to the field of gene detection technology. The present invention relates to a primer pair for detecting the DNA methylation level of the promoter of the sheep KAP8 gene, and the sequence of the primer pair is shown in SEQ ID NO: 1-2. The primer pair can be used to specifically detect the DNA methylation level of the promoter region of the KAP8 gene of different breeds of sheep. The DNA methylation level of the region can be used to determine the thickness of sheep wool fibers, providing a scientific basis for later sheep breeding and selection.

The invention discloses a composition for polygene methylation detection of early prostate cancer, the composition is an EFEMP1 and MIR-193B promoter combined gene, the base sequence of the EFEMP1 gene is SEQ ID No: 1 or SEQ ID No: 2, and the base sequence of the MIR-193B promoter combined gene is SEQ ID No: 1 or SEQ ID No: 2. The base sequence of the MIR-193B promoter is shown as SEQ ID No: 3 or SEQ ID No: 4; meanwhile, the invention further provides a kit for detecting methylation of the EFEMP1 gene and the MIR-193b promoter, the sensitivity for detecting prostatic cancer patients reaches 96.8%, and the specificity is 94.6% or above.

This specification describes diagnostic methods for selecting treatments for personalized cancer therapy by simultaneously detecting genomic and epigenomic characteristics from a single patient sample, including the quantification of promoter methylation, as well as applications for confirming methylation patterns associated with epigenetic allele status. This specification also describes methods comprising the steps of detecting methylation in one or more promoter regions of at least one of multiple genes, and generating multiple methylation calls to quantify methylation in one or more promoter regions.

The invention relates to a kit for rapidly and quantitatively detecting methylation of an EB (Epstein-Barr) virus C promoter, and belongs to the technical field of gene detection. The kit comprises two pairs of specific primers for amplifying the EB virus C promoter sequence, a methylation detection probe, a universal detection probe, an unmethylated standard substance and a calibrator. According to the kit disclosed by the invention, the MSRE technology is optimized and improved, so that the MSRE technology and the qPCR technology can be subjected to an integrated reaction, and rapid, simple and convenient quantitative detection on Cp methylation is achieved. According to the invention, a calculation and calibration mode of the digestion efficiency of MSRE detection is provided for the first time, the contained calibrator can calibrate an original qPCR result, and the unmethylated standard substance can realize monitoring of the digestion efficiency of MSRE and secondary calibration of the result, so that the accuracy of the result is remarkably improved, and technical support is provided for early accurate screening of nasopharyngeal carcinoma.

The invention discloses application of an APOA1 gene promoter methylation accelerant in preparation of a medicine for promoting placenta angiogenesis, and belongs to the technical field of biology. The regulation and control mechanism of the APOA1 gene on placenta angiogenesis is clarified from the molecular level for the first time, it is found that expression of the APOA1 gene is regulated and controlled by betaine and LMNB2, and a new treatment target and a new intervention strategy are provided for improving placenta-related pathological conditions; the invention provides important theoretical basis and technical support for developing products for preventing or improving the outcome of bad pregnancy, and provides theoretical basis and potential drug research and development direction for healthy development of fetuses.

The invention is in the field of molecular biology and medical diagnosis. It provides means and methods for determ- ining the prognosis and disease outcome of a subject having a melanoma. More in particular, it provides a method for determining whether a subject having a melanoma has a poor prognosis, the method comprising the step of determining in a sample from the sub- ject whether the LY75 promoter is methylated and if the LY75 promoter is methylated, classifying the subject as having a poor pro- gnosis.

This invention belongs to the field of plant genetic engineering technology, specifically involving SsuTDX The application of gene promoter methylation in regulating hemicellulose synthesis. This invention discloses... SsuTDX The application of gene promoter methylation in regulating hemicellulose synthesis, among which SsuTDX The promoter methylation region of the gene has a nucleotide sequence as shown in SEQ ID NO.1. SsuTDX High levels of gene promoter methylation inhibit hemicellulose synthesis; SsuTDX Low methylation levels in the gene promoter promote hemicellulose synthesis. Furthermore, methylation in this region affects SsuMYB295 binding, and temperature can positively regulate methylation levels. This invention provides molecular targets and specific methods for precisely regulating hemicellulose synthesis in *Symplocos edulis*, laying the foundation for targeted breeding of long-fiber varieties, genetic improvement, and material optimization, and has significant practical value.

The invention relates to a reagent for improving the methylation level of a FANCB promoter and application, and particularly provides an epigenetic editing reagent which enables the methylation level of a FANCB promoter region to be increased, so that FANCB is inactivated, and then ovarian cancer is treated and the drug sensitivity of the ovarian cancer is increased.

This invention belongs to the field of biomedical technology, specifically providing the application of TL1A as a biomarker in the diagnosis of cirrhosis. This invention is the first to discover that the TL1A gene promoter exhibits a hypomethylated state in patients with hepatitis B-related cirrhosis, suggesting a close correlation between the methylation level of the TL1A gene promoter and the diagnosis of hepatitis B-related cirrhosis. Therefore, quantitative detection of TL1A gene promoter methylation can indicate the occurrence and progression of hepatitis B-related cirrhosis, thereby assisting in clinical diagnosis and possessing significant practical application value.

The invention relates to a reagent for improving the methylation level of a BRCA1 promoter and application, and particularly provides an epigenetic editing reagent which enables the methylation level of a BRCA1 promoter region to be increased, so that BRCA1 is inactivated, and then ovarian cancer is treated and the drug sensitivity of the ovarian cancer is increased.

In implementations described herein, methylation information is determined with respect to classification regions of a reference genome that are related to the presence of a tumor in a subject. The methylation information can be analyzed using a number of computational techniques to provide metrics related to the presence or absence of a tumor in a given subject, including a determination of tumor fraction.

The invention discloses application of RG108 in heart transplantation immunosuppression by regulating T cell functions, and relates to the technical field of medical bioengineering. The invention innovatively provides a method for inhibiting the activity of DNA methyltransferase 1 (DNMT1) by using a small molecule compound RG108, and by reducing the methylation level of a CDKN1A gene promoter, restoring the expression of the promoter and inducing T cells to enter an aging state, the proliferation and effect activity of the promoter is reduced, and rejection reaction is inhibited. The RG108 is a non-nucleoside DNMT1 selective inhibitor with a clear structure, the activity of the inhibitor is inhibited by combining with a catalytic structural domain, DNA is not doped, off-target toxicity is not caused, and the RG108 is an ideal molecule for realizing controllable and reversible epigenetic regulation. A new transplantation immune tolerance strategy is established, and the defects that an existing immunosuppressor is large in side effect and cannot induce immune memory tolerance are overcome.

The invention discloses TERC promoter methylation and application thereof in non-small cell lung cancer diagnosis and prognosis, and relates to the technical field of biological medicine. It is found that the methylation level of the TERC promoter is reduced in non-small cell lung cancer tissues, TERC methylation modification is remarkably changed in most of the non-small cell lung cancer tissues, and universal detection of tumors in different stages can be achieved; the low methylation state of a key site in a promoter region is specifically captured, so that cancer tissues and normal lung tissues are effectively distinguished, and a reliable basis is provided for clinical definite diagnosis. The kit for detecting the methylation of the DNA sequence of the TERC promoter can specifically detect the DNA methylation level of the TERC promoter, and can also specifically and quantitatively detect the DNA methylation level of the TERC promoter; the detection result can provide an evaluation method for the condition and individualized medication monitoring of non-small cell lung cancer patients, the early diagnosis of tumors, and the prognosis detection of the patients on drug therapy.

The invention provides regulation and control application in liver cancer cells based on BHMT and PPAR gamma methylation, and relates to the technical field of biological medicines. The invention verifies that the content of the BHMT in liver cancer tissues is obviously reduced, and the content of the BHMT in cancer tissues of MVI patients is obviously reduced, which indicates that the BHMT can be used as a biomarker for predicting and evaluating the MVI occurrence probability of the liver cancer patients. The invention also verifies that the overexpressed BHMT can significantly inhibit the proliferation and transfer ability of hepatoma carcinoma cells in vivo, and verifies that the knockout of BHMT leads to enrichment of PPAR signal pathways in hepatoma carcinoma cells and the expression of PPAR gamma is significantly increased by researching the action relationship between BHMT and PPAR gamma signal pathways; the expression level of SAM can be remarkably improved by overexpressing BHMT, so that the methylation level of a PPAR gamma promoter is up-regulated, and the purpose of inhibiting PPAR gamma expression is achieved. The results show that in the development stage of liver cancer after formation, the drug over-expressing BHMT can inhibit proliferation and migration of liver cancer cells by inhibiting the expression level of PPAR gamma. The invention provides a new treatment thought and method for treating liver cancer and predicting postoperative metastasis and recurrence.